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Dynamics
Mathematical modelines have shown the greatest potential to protect against simian immunode-
ﬁciency virus (SIV) infection, a model for human immunodeﬁciency virus (HIV). Immunity against the
vaccine virus is thought to mediate protection. However, it is shown computationally that the opposite
might be true. According to the model, the initial growth of the challenge strain, its peak load, and its
potential to be pathogenic is higher if immunity against the vaccine virus is stronger. This is because the
initial growth of the challenge strain is mainly determined by virus competition rather than immune
suppression. The stronger the immunity against the vaccine strain, the weaker its competitive ability
relative to the challenge strain, and the lower the level of protection. If the vaccine virus does protect the
host against a challenge, it is because the competitive interactions between the viruses inhibit the initial
growth of the challenge strain. According to these arguments, an inverse correlation between the level of
attenuation and the level of protection is expected, and this has indeed been observed in experimental
data.
© 2008 Elsevier Inc. All rights reserved.Introduction
Containment of the human immunodeﬁciency virus (HIV) epi-
demic would require an effective vaccine that blocks infection or
signiﬁcantly delays the rate of progression to AIDS (Duerr, Wasserheit,
and Corey, 2006; Klausner et al., 2003; Letvin, 1998). While ex-
perimental vaccines have generally shown disappointing results,
live attenuated virus vaccines have shown the best levels of protec-
tion in monkeys infected with simian immunodeﬁciency virus (SIV)
(Almond et al., 1995; Daniel et al., 1992; Koff et al., 2006), although
safety issues remain to be resolved (Hofmann-Lehmann et al., 2003;
Ruprecht, 1999; Whitney and Ruprecht, 2004). While such attenua-
ted viruses are replication impaired, they still establish a persistent
infection in the patient, which carries a long-term risk of re-gaining
pathogenic potential (Letvin, 1998; Ruprecht et al., 1996). At the same
time, it is this persistence that is thought to promote protection in
vaccinated animals. Even if the infection itself is not prevented,
infection of vaccinated individuals can lead to relatively low virus
loads and a slower rate of disease progression (Koff et al., 2006). The
mechanisms underlying this protection are, however, unclear (John-
son and Desrosiers, 1998; Koff et al., 2006; Stahl-Hennig et al., 2007;
Wyand et al., 1999). The attenuated virus is thought to induce im-l rights reserved.mune responses that can down-modulate early viral replication
upon infection with a challenge strain (Gauduin et al., 1998; Metzner
et al., 2000). However, the level of immune responses has not been
found to correlate with the level of protection observed (Marthas
et al., 1992; Stahl-Hennig et al., 2007). In addition, other puzzling
ﬁndings have been reported: for example that the level of protection
correlates inversely with the level of vaccine attenuation (Johnson
et al., 1999). Using an established mathematical model of virus dy-
namics (Nowak and Bangham, 1996; Perelson, 2002), it is shown that
the extent of initial growth of the challenge virus is not limited by
immunity, but predominantly by competition between the challenge
and the vaccine virus for target cells. Counter-intuitively, it can be
shown that stronger immunity against the vaccine virus results in a
faster initial growth rate of the challenge strain, which is likely to
correlate with a reduced probability of protection. These ﬁndings
shed new light onto how live attenuated SIV/HIV vaccines work, and
they can also reconcile some of the experimental data that have
remained unexplained so far.
Results and discussion
The basic model
A mathematical model is constructed that describes infection
with a live attenuated virus and a challenge strain. Denote suscep-
tible cells by x, cells infected by the vaccine virus by y1, cells infec-
ted by the challenge virus by y2, and a speciﬁc immune response
by z. The infection dynamics model is given by the following set of
Fig. 1. Dynamics of HIV/SIV challenge in a host infected with a live attenuated virus
vaccine, according to the basic model. Stronger and weaker immune control of the
vaccine virus is compared. (a) Kinetics of virus growth. Stronger immunity against the
vaccine virus leads to faster initial virus growth and a higher peak virus load of the
challenge strain. (b) Total number of infection events undergone by the challenge virus
as a function of time, which correlates with the total number of mutants generated by
the challenge strain (because mutation occurs during reverse transcription, which in
turn occurs upon infection). The plot basically integrates over β2xy2. Stronger immunity
against the vaccine virus leads tomore infection events and thus to ahigher chance that a
mutant is generated that escapes the immune responses. If an escape mutant is
generated, virus loadwill rise to higher values (not shownhere). If, on the other hand, no
escape mutant arises during the initial growth phase, the virus will eventually converge
to an equilibrium that describes immune control, as shown in part (a). Parameters were
chosen as follows. λ=0.1, d=0.001, a=0.002, β1=0.005, β2=0.05, b=0.05, p=1. For strong
immune control of the vaccine virus, c1=0.02. For weak immunity against the vaccine
virus, c1=0.005. The immune responsiveness against the challenge strain is assumed to
be c2=0.05. The units of the axes are arbitrary and parameter values have been chosen
for illustrative purposes, as most parameter values are unknown.
300 D. Wodarz / Virology 378 (2008) 299–305differential equations, which are based on well-established mathe-
matical models of virus dynamics (Nowak and Bangham, 1996; Perel-
son, 2002):
dx=dt = λ−dx−x β1y1 + β2y2ð Þ
dy1=dt = β1xy1−a1y1−p1y1z
dy2=dt = β2xy2−a2y2−p2y2z
dz=dt = F y1;y2;z
 
−bz:
Susceptible cells are produced with a rate λ, die with a rate d, and
become infected by the vaccine or challenge strain with a rate β1 and
β2, respectively. Cells infected with the vaccine and the challenge
strain die with a rate a1 and a2, respectively. The free virus is assumed
to be in a quasi steady state, proportional to the number of infected
cells. Therefore, the parameters β1 and β2 summarize not only the
rate of infection, but the overall replication rate of the vaccine and thechallenge virus. This includes the rate at which infected cells produce
viruses that are transmitted to new cells. For details, see (Nowak and
May, 2000;Wodarz, 2007). The challenge virus is assumed to replicate
faster than the vaccine virus (β2Nβ1). Speciﬁc immune responses
against the virus rise with a rate that can potentially be proportional
to virus load and the number of immune cells. This can be described
by a variety of mathematical functions, F(y1,y2,z). For simplicity, as-
sume F(y1,y2,z)=(c1y1+c2y2)z, as described in (Nowak and Bangham,
1996), although more complex immune proliferation terms (De Boer
and Perelson, 1998) do not alter basic results (see Methods). Such
immune responses could be either T cell responses or B cell responses
that directly and speciﬁcally respond to and attack the virus. For the
analysis, complete immunological cross-reactivity between the virus
strains is assumed, i.e. p1=p2 (this can be relaxed, see below). As-
sumptions and robustness are further described in Methods.
In this model, the vaccine virus can establish a persistent infection
if β1λ / (da1)N1, that is its basic reproductive ratio (Nowak and May,
2000; Wodarz, 2007) needs to be greater than one. The immune
response against the virus becomes established if c(λ /a1−d /β1)Nb,
which is the invasion condition for the immune response z from
low numbers. In this case, the infection will eventually equilibrate
around the following levels: x(1)=λc1 / (dc1+β1b), y1(1)=b /c1, y2(1)=0,
z(1)=(β1x(1)−a1) /p. These are all basic properties of virus dynamics
equations that have beenworked out in the past (Nowak andBangham,
1996; Perelson, 2002). So far, this type of mathematical framework
has only been applied to live attenuated virus vaccines in one other
study with a very different focus, in the context of post-exposure
vaccination (Bonhoeffer and Nowak, 1995). Also, mathematical mo-
deling has been used to examine the competition dynamics between
wild-type and replication-impaired HIV strains (Altes and Jansen,
2000; Bagnoli et al., 2006; Ball et al., 2007; Smith and Wahl, 2005),
again with a different focus in mind.
The initial growth rate of the challenge virus is given by r=x(1)(β2−
β1)−a2+a1, where x(1) denotes the equilibrium number of uninfected
cells in the presence of the vaccine virus, as deﬁned above. The chal-
lenge virus grows if rN0. In this case, the following properties are
observed. A higher number of uninfected cells in the presence of the
vaccine virus, x(1), correlates with a faster initial growth rate of the
challenge virus. Because x(1)= λc1/(dc1+β1b), a stronger immune re-
sponse against the vaccine virus (higher value of c1) leads to a higher
number of uninfected cells, and thus to a faster initial growth rate and a
higher peak load of the challenge virus (Figs.1a, 3a). Because faster virus
replication leads to a faster accumulation of mutations by the virus,
stronger immunity against the vaccine virus leads to a higher average
number of mutants generated by the challenge virus during its initial
growth (Fig. 1b). Therefore, the stronger the established immunity, the
more likely it is that the challenge virus can escape or impair immunity
during the initial growth, leading to reduced protection. This is because
virus competition rather than immunity drives the initial growth rate of
the challenge strain. The number of uninfected target cells left by the
vaccine virus is the important determinant. This is also reﬂected by the
fact that a faster replication rate of the vaccine strain slows down the
growth rate of the challenge strain. Of course, if the virus fails to escape
or impair immunity during the initial growth, then the previously
established immunity contains virus load at relatively low levels in the
long term, as shown by the convergence to equilibrium in Fig. 1a.
Fig. 2 presents in more detail the dynamics of the vaccine and
challenge strain, as well as the immune response. The ﬁgure plots
the dynamics both for a strong and a weak immune response against
the vaccine virus. Before the challenge, virus load and the immune
response are at equilibrium, as described by the expressions x(1), y1(1),
and z(1) above. Upon challenge, the new virus replicates to a peak and
eventually converges to a steady state. At the same time, the vaccine virus
declines to extinction in the model. This is because the two viruses
compete for the same target cell pool, and the faster replicating challenge
strain is superior and excludes the slower replicating vaccine strain. In
Fig. 2. Time series that documents that dynamics of the two viruses and the immune response upon challenge. The simulations are based on the basic model described in the text. The
number of immune cells corresponds to speciﬁc immune effector cell populations that ﬁght the virus, such as B cells or T cell. Simulations are shown for (a) stronger immunity against the
vaccine virus (higher value of c1) and weaker immunity against the vaccine virus (lower value of c1). Parameters were chosen as follows: λ=0.1, d=0.001, a=0.002, β1=0.005, β2=0.05,
b=0.05, p=1. For strong immune control of the vaccine virus, c1=0.02. For weak immunity against the vaccine virus, c1=0.005. The immune responsiveness against the challenge strain is
assumed to be c2=0.05. The units of the axes are arbitrary and parameter values have been chosen for illustrative purposes, as most parameter values are unknown.
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extinct or goes extinct more slowly because of reservoirs inwhich viruses
can survive for prolonged periods of time, such as latently infected cells.
These are not included in the model for simplicity. The immune response
follows the dynamics of the challenge virus. It starts from the equilibrium
level at which it controls the vaccine virus. It then expands and converges
towards a new equilibrium. In the simulation shown in Fig. 2, the number
of immune cells at this new equilibrium is higher than before, because of
the particular choice of parameters. That is, the immune response was
assumed to react faster against the challenge strain, for example because
attenuation might cause lack of immunogenicity. However, for other
parameter values, the number of immune cells after infection with the
challenge virus can also be lower than observed with the vaccine virus,
for example because of increased immune-impairment caused by the
challenge virus. Overall conclusions do not depend on these details. Other
aspects of robustness will be discussed further below. The equilibrium, to
which the dynamics converge after infection with the challenge strain is
given by the following expressions: x(2)=λc2/(dc2+β2b), y1(2)=b/c2, y2(1)=0,
z(2)=(β2x(2)−a2)/p. These patterns are observed both for weak and for
strong immunity against the vaccine strain (Fig. 2).
In the context of the simple model analyzed here, the behavior
described above is observed over a wide parameter space, and it can
be argued that it applies to the entire parameter space that isbiologically realistic. The analysis so far was performed with the
assumption that p1=p2 (the vaccine and challenge viruses are
removed by immune responses with the same rate). Under this
assumption, the arguments hold if β2Nβ1, i.e. the replication rate of
the challenge strain β2 is faster than the replication rate of the vaccine
strain β1. This is likely to be true, since the vaccine virus is attenuated
while the challenge virus is not. In the more general case where the
two viruses can be removed with different rates, the same arguments
hold if p2/p1Nβ2 /β1. In words, the increase in the rate of immune
attack of the challenge strain needs to be higher than the increase in
the replication rate of the challenge strain relative to the vaccine virus.
If this is the case, then stronger immunity leads to slower growth of
the challenge strain and therefore to increased protection. For
example, if the challenge strain replicates twice as fast as the vaccine
virus, then the challenge strain needs to be removed by immune
responses more than twice as fast as the vaccine virus for the results
described here to break down. This might be a biologically unrealistic
assumption in the light of data that report sub-optimal immune-
mediated effector responses against HIV/SIV, for example in the
context of CD8 T cell mediated killing (Asquith et al., 2006).
In summary, the results described here give rise to a tradeoff:
The weaker the degree of vaccine attenuation (including immu-
nological control), the higher the chances that the challenge virus
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the vaccine strain is increased relative to that of the challenge
strain. Such an inverse relationship between vaccine attenuation
and protection has been reported in experimental data (Johnson et
al., 1999). Other experimental data also support the theoretical
notion that virus competition might be an important determinant
of protection and that immune responses against the vaccine strain
might not contribute signiﬁcantly to the outcome of a challenge.
For example, it has been found that CD8 T cell depletion beforeand upon challenge did not lower the degree of protection
observed with a live attenuated vaccine (Stebbings et al., 2005,
1998; Whitney and Ruprecht, 2004), indicating that this branch of
the immune system does not determine the level of protection
observed. Similarly, protection by live attenuated SIV has been
observed in the absence of neutralizing antibodies (Stebbings et al.,
2004). In a recent study, the level of antibody or CD8 T cell
responses did not correlate with the outcome of a challenge
following vaccination with a live attenuated SIV strain (Mansﬁeld
et al., 2008). Several monkeys that were well protected did not
show signiﬁcant levels of adaptive immune responses. On the
other hand, several animals that were characterized by the
presence of a substantial amount of immunity against the vaccine
strain were not protected well against a challenge. This is
consistent with earlier work that also did not ﬁnd a correlation
between the level of immune responses and the degree of
protection observed (Stahl-Hennig et al., 2007). If the established
immune responses were protecting against challenges, then larger
immune cell populations would be more protective. On the other
hand, if virus competition drives the challenge dynamics, then no
obvious correlation between the level of immunity and the level of
protection is expected. Instead, the level of protection should
correlate with the number of target cells available for infection by
the challenge virus, which is determined by a variety of host and
viral parameters (Nowak and Bangham, 1996; Nowak and May,
2000).
While such data leave open many questions about the determi-
nants of challenge outcome after vaccination with a live attenuated
virus, the theory presented here provides a ﬁrst step to interpreting
these data. At the moment it is not possible to further evaluate and
validate the model against data, since this will require difﬁcult new
experiments, which directly tests the competition dynamics between
the vaccine and the challenge virus in the context of protection. This is
very hard to achieve with in vivo experiments because one has to rule
out differences in immunity. The immune cell depletion experiments
discussed above (Stebbings et al., 2005) are consistent with the model
so far, but more extensive studies have to be performed for further
validation, including more data points that document the growth of
the challenge virus upon infection. However, the notion that virus
competition and not immunity might be an important correlate of
protection can help us think in a different way about the complex
experimental results regarding the relationship between immunity
and protection. At the same time, it raises questions about the
feasibility of live attenuated HIV vaccines for clinical use. Making the
vaccine virus more competitive by having too little attenuation raises
serious safety concerns (Hofmann-Lehmann et al., 2003; Ruprecht,
1999;Whitney and Ruprecht, 2004). A higher vaccine virus loadmight
directly lead to pathogenicity (Ruprecht et al., 1996), or it might enable
the virus to acquire mutations that confer a heightened degree of
virulence. This poses limitations for designing an optimal live
attenuated vaccine against HIV.Fig. 3. The initial growth rate of the challenge strain (r, deﬁned in text) as a function of
the immune responsiveness c1 against the vaccine virus (i.e. the strength of speciﬁc
immune response against the vaccine virus). This is done for three scenarios. (a) The
basic model. A higher immune responsiveness correlates with a higher growth rate of
the challenge strain. (b) Coinfection model. As the immune responsiveness is increased,
the initial growth rate of the challenge virus ﬁrst declines and then rises again.
(c) Model which assumes that HIV activates its own target cells. At ﬁrst, an increase in
the immune responsiveness leads to a higher initial growth rate of the challenge virus,
but for strong immunity, a further increase in the responsiveness leads to a decline in
the growth rate of the challenge virus. This is because lower vaccine virus loads in this
parameter region maintain a lower number of activated target cells. Parameters were
chosen as follows. For panels (a) and (b): λ=0.1, d=0.001, a=0.002, β1=0.005, β2=0.05,
b=0.05, p=1. For panel (c): η=1, ξ=1, f=0.01, r=0.5, d=0.1, β=1, a=0.1, p=1, b=0.1. The
units of the axes are arbitrary and parameter values have been chosen for illustrative
purposes, as most parameter values are unknown.
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The last section considered a basic model of virus infection in vivo
and obtained insights about the dynamics of live attenuated virus
vaccines and subsequent challenges. This section introduces more
biological complexity into the model to examine how those insights
hold up and under what circumstances the above obtained insights
are altered. In particular, two features of HIV infection will be
considered: (i) the ability of multiple HIV particles to infect the
same target cell, and (ii) the fact that target cells for HIV are immune
helper cells that themselves can be induced to divide by antigenic
stimulation.
Coinfection
Consider multiple infection of target cells ﬁrst, also known as
coinfection (Chen et al., 2005; Dang et al., 2004; Jung et al., 2002; Levy
et al., 2004). Importantly in this context, the challenge virus can infect
not only uninfected cells, but also wild-type infected cells. A
mathematical model that examines the basic kinetics of coinfection
has been examined by (Dixit and Perelson, 2005), and a model that
studies the competition between two HIV strains in the presence of
coinfection has been studied by (Wodarz and Levy, 2007). Here, a very
simple modeling approach is taken in order to investigate the impact
of coinfection on the results described here. Coinfection will be
considered in the context of two virus strains. The rate of spread of the
challenge strain will be determined, assuming that the vaccine virus
and immune cell populations have equilibrated. In the presence of
coinfection, the equations for the growth of the challenge strain can be
written as dy2/dt=β2y2(x+y1)−a2y2−p2y2z. Instead of just replicating
in uninfected target cells, x, the challenge virus can also replicate in
vaccine virus infected cells, y1. Only the short term dynamics that
describe the initial growth of the challenge strain will be described.
The long-term dynamics will not be considered, and so the effect of
the vaccine virus replicating in cells infected by the challenge strain
does not need to be included. Basically, coinfection changes the exact
long-term competition dynamics. In the absence of coinfection, the
faster replicating challenge strain outcompetes the slower vaccine
strain. In the presence of coinfection, it is possible for the slower
replicating vaccine virus to persist at relatively low levels rather than
to go extinct. For a full analysis of how coinfection inﬂuences the
outcome of competition, the reader is referred to Wodarz and Levy
(2007). The initial growth rate of the challenge virus in the context of
coinfection is proportional to the sum of uninfected and infected cells,
x+y1. This shows the following dependence on the strength of the
immune response against the vaccine virus (Fig. 3b). As the strength
of the immune response is increased, x+y1 can ﬁrst decline to a
minimum and can then rise again. If the immune response is weak
(low value of c1), the number of uninfected cells is low, but the
number of infected cells is higher. This leads to relatively fast
challenge virus spread through coinfection (Fig. 3b). If the immune
response is relatively strong (high value of c1), many uninfected cells
are availablewhile the number of infected cells is low. Again, this leads
to relatively fast challenge virus spread. For an intermediate strength
of the immune system, the overall number of target cells is lowest and
the spread of the challenge virus is slowest. Therefore, in this case,
weakening immunity does not lead monotonically to better protec-
tion. Very weak immunity leads to high vaccine virus loads, and thus
overall to more cells available for infection. Note, however, that this is
not a universal pattern and only holds if the rate of virus-induced cell
killing a1 lies below a threshold relative to the viral replication rate, β1,
i.e. if a1b (λβ1)1/2 (Wodarz and Krakauer, 2000). If this is not the case,
i.e. if the virus kills its cells with a relatively fast rate, then reducing
immunity monotonically leads to a reduction in the overall number of
target cells, and the results remain qualitatively the same as in the
simpler model without coinfection. Further note, that the dependence
on the strength of the immune response described here does nottranslate into a dependence on the degree of attenuation in general.
A higher vaccine virus attenuation through a reduction in the viral
replication rate always leads monotonically to faster challenge virus
growth and thus to less efﬁcient protection, as in the context of the
simple model. Finally, whether coinfection indeed turns out to be an
important driving force in the dynamics of HIV infection remains to be
determined by further experimental work, and the modeling effort
presented here has to be interpreted with this in mind.
Infection of HIV-speciﬁc immune cells
Now a model extension is considered that is very relevant to HIV:
the assumption that the target cells of the virus are immune cells that
can themselves expand in response to antigenic stimulation. These are
the CD4 T helper cells. In particular it has been shown that HIV might
not infect all helper cells equally, but that it could preferentially infect
HIV-speciﬁc T helper cells (Douek et al., 2002). These processes can be
captured by models in a variety of ways. Here, a model described by
(Wodarz et al., 1999) will be considered. Denote the population of
resting T helper cells by s, the population of activated T helper cells by
x, the population of infected helper cells by y, and an effector immune
response by z. The model given by the following set of differential
equations.
ds=dt = n−fs−rs y1 + y2ð Þ
dx=dt = rs y1 + y2ð Þ−dx−x β1y1 + β2y2ð Þ
dy1=dt = η + β1xy1−α1y1−p1y1z
dy2=dt = η + β2xy2−α2y2−p2y2z
dz=dt = z c1y1 + c2y2ð Þ−bz:
The model distinguishes between resting and activated T helper
cells. It is further assumed that cell activation is stimulated by HIV
itself. This is in accord with data that demonstrated preferential
infection of HIV-speciﬁc T cells by the virus (Douek et al., 2002).
However, the population x could also include other T cells that are
activated by HIV through bystander effects. A more complete model
would include a population of alternative target cells that do not
require activation for infection, for example macrophages or dendritic
cells. Such a more complete model is analyzed in (Wodarz et al., 1999).
For the current purpose, a simpliﬁcation is considered and it is
assumed that in addition to the T cell infection described in themodel,
an inﬂux of infected cells occurs with a rate ηi, arising from virus
replication in those alternative target cells. This simpliﬁed model has
the same basic properties as the more extensive model described in
(Wodarz et al., 1999).
Thus, resting helper cells are produced with a rate ξ, die with a rate
f, and become activated by antigen with a rate r. Activated T cells die
with a rate d, and become infected by the different virus strains with a
rate β1 and β2, respectively. Infected cells are further produced by
replication in alternative target cells with a rate η1 and η2, respectively.
Infected cells die with a rate a1 and a2 respectively. The immune
response expands upon stimulation by the vaccine virus with a rate c1
and by the challenge virus with a rate c2. The immune response decays
in the absence of antigen with a rate b. For simplicity, coinfection is
not included in this model.
Parameter regions are considered in which the dynamics between
the vaccine virus and the immune responses converge towards a stable
equilibrium inwhich both populations persist. As in the simplemodel,
the growth rate of the challenge strain is proportional to the number of
uninfected susceptible target cells at the time of the challenge, when
the dynamics between the vaccine virus and the immune response
have equilibrated. In the current model, these are the cells which
become activated through stimulation by HIV, x. In this case, the
dependency of the number of activated cells on the strength of
immune-mediated vaccine virus control is as follows (Fig. 3c). If the
degree of immune-mediated control is increased, the number of
susceptible target cells, and thus the growth rate of the challenge virus,
rise at ﬁrst as in the simple model. Hence, stronger immunity again
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responses, however, a higher degree of immune-mediated vaccine
virus control leads to a decline in the number of susceptible target cells
and thus in the growth rate of the challenge virus (Fig. 3c). Therefore, in
this parameter region stronger immunity correlates with a higher
degree of protection. The reason for this one-humped relationship is as
follows. On the one hand, the virus population reduces the number of
susceptible target cells. Hence, stronger immunity and lower vaccine
virus load leads to less infection, which in turn leads to a higher
number of target cells. On the other hand, the existence of susceptible
target cells depends on cell activation and thus on stimulation by the
virus. As vaccine virus control becomes very efﬁcient, not enough virus
is around to maintain the population of susceptible target cells at
high levels, leading to a decline in this population. A one-humped
relationship between virus load and the level of CD4 T helper cell
responses has actually been observed in the context of SIV infected
macaques that received anti-retroviral therapy during the acute phase
of the infection (Wodarz et al., 2000). Animals treated 24 h after
infection showed an unusually high degree of virus control by HIV-
speciﬁc immune responses. They were also protected both against
homologous and heterologous re-challenges as long as one year after
the initial infection (Lifson et al., 2003, 2000). Re-challenge resulted
in a blunted peak load of the challenge virus, followed by down-
regulation to undetectable levels. On the otherhand, animals thatwere
treated 72 h after infection showed much less efﬁcient virus control
and higher virus loads (Lifson et al., 2000). Among animals that con-
trolled the virus less efﬁciently, a higher degree of immunological
control and lower virus loads correlated with a higher number of HIV-
speciﬁc CD4 Tcells. According themodel this is because more immune
control leads to less T cell infection, which in turn leads to a higher
number of T cells. Among the animals that controlled the virus very
efﬁciently, however, the opposite correlation was observed: stronger
immunological control and lower virus loads correlated with a lower
number of HIV-speciﬁc helper T cells. According to the model, the
reason is that the very low virus loads did not provide sufﬁcient
stimulation to maintain the speciﬁc helper T cell population at higher
levels (Wodarz et al., 2000). These data (Wodarz et al., 2000), however,
indicate that this pattern is only observed in the context of highly
efﬁcient virus suppression, which is not typically observed. These
arguments can reconcile an apparent contradiction: While it has
been found that the degree of vaccine attenuation is inversely cor-
related with the level of protection (Johnson et al., 1999), strong
immune-mediated virus suppression resulted in very efﬁcient protec-
tion against re-infection in the context of the monkeys that were
treated 24 h after infection and that showed exceptional degrees of
virus control (Lifson et al., 2003, 2000). In both cases, virus competition
determines the degree of protection; the treatment 24 h after infection
pushed the animals into the unusual parameter space where not
enough stimulation remained to maintain higher numbers of target
cells, thus reducing the relative replication rate of the challenge virus.
Conclusions
In conclusion, the model analyzed here challenges some common
lines of thought regarding the mechanisms underlying live attenuated
HIV/SIV vaccines. According to the model, it is not the immunity
established against the vaccine virus that can protect the host against a
challenge. In fact, stronger immunity can lead to worse protection.
Instead, if the vaccine virus protects the host against a challenge, it is
because competitive interactions among the viruses inhibit the initial
spread of the challenge virus. However, the degree of immunity does
not always correlate negatively with the amount of protection in the
model, depending on the exact assumptions of the model. If the
challenge virus can productively infect cells that are already infected
with the vaccine strain, then the growth rate of the challenge strain can
go up at low levels of immunity against the vaccine strain, thus leadingto reduced protection. In this case, slowest growth of the challenge
virus, and thus the best protection, is observed for an intermediate
strength of the immune response against the vaccine virus. If it is
assumed that HIV predominantly infects cells that are activated by
itself, then a strong degree of immunity can lead to a reduced growth
rate of the challenge strain and thus to increased protection. This is
because lower virus load, brought about by stronger immunity, can
onlymaintain a fewactivated target cells, thus reducing the replicative
potential of the challenge virus. However, data indicate that this pa-
rameter region only applies to cases of exceptional virus control, as has
been observed in SIV infected monkeys treated 24 h after infection.
Perhaps HIV infected patients that are long term non-progressors also
fall into this category. Despite these deviations, however, the result
remains that virus competition determines the degree of protection.
Even in the case where strong immunity leads to higher degrees of
protection, this occurs because of a reduction in the number of target
cells.
This notion should ideally be tested by experiments that can separate
the effects of competition and immune-mediated protection, especially
because the strength of the immune response determines the level at
which the vaccine virus persists and how many uninfected cells remain
available. Perhaps the degree of protection conferred by different vaccine
viruses could be investigated in the context of long-term immune
suppression inmore detail, based on the experiments by (Stebbings et al.,
2005). If the results describedhere are true, then life attenuatedviruses do
not present a feasible clinical option, even if the potential problems arising
from the presence of a persisting vaccine virus could be overcome. The
amount of protection correlates with the danger of the vaccine strain to
the patient. However, it is important to note that the story would be very
different for a life vaccine virus that is not based inHIV, but that is given by
a relatively harmless virus which can persist and carry the relevant HIV
epitopes. It would be important that such a virus does not infect the same
target cells as HIV, so that no virus competition occurs. In such a scenario,
the anti-HIV immune response generated by the vaccine virus would be
responsible for protection. The persistence of the virus could keep the
immune response in an alert state and contribute to immediate anti-viral
activity upon infection, although the downside would be to harbor a
persistent virus in the long term.
Methods
The mathematical model that was analyzed is described in the
main text, along with a discussion of dependence on parameters and
robustness. Here, some additional details are provided that are
important to keep in mind when interpreting the model predictions.
One of the problemswith allmodels that take into account immune
responses is the fact that it is not exactly known how the process of
immune expansion should be described mathematically. In persistent
infections, it seems clear that the division of immune cells is promoted
by the presence of antigen. In the simplest form, the rate of immune
expansion can be described by (c1y1+c2y2)z, and this has been used
here for illustrative purposes. However, simulations have been run
with alternative immune expansion terms that contain various sa-
turation terms, and results remained robust. Examples are (c1y1+c2y2)
z/(z+ɛ), (c1y1+ c2y2)/(y1+y2+ɛ), or (c1y1+c2y2)/(z+y1+y2+ɛ). Such
more-complex models with saturation tend to show more stable
dynamics and are probably more realistic, but are more difﬁcult to
analyze.
In certain parameter regions, where immunity is very weak, the
challenge virus growsmonotonically towards a steady state, instead of
ﬁrst growing towards a peak. In this case, the arguments about peak
virus load are obviously not valid. Such parameter regions are, how-
ever, not likely to be realistic because infection of a host with SIV/HIV
tends to involve growth towards a peak.
The difference in the growth rate of the challenge virus in the
presence of stronger and weaker immunity diminishes as the rate of
305D. Wodarz / Virology 378 (2008) 299–305target cell production, λ, becomes faster. However, during the initial
growth phase of the challenge virus, it is not likely that much target
cell production occurs. Therefore, this is not a realistic regime.
Finally, a note on the ﬁgures that are presented in this paper: The
parameter values used to plot the graphs are chosen for illustrative
purposes, since most parameter values of this system are uncertain.
Therefore, the axes are given in arbitrary units. However, the para-
meter regions in which the illustrated patterns hold, and when they
break down, are discussed extensively in the text.
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